Medicenna Therapeutics
David Hyman, CA, CBV, currently serves as Chief Financial Officer at Medicenna Therapeutics Corp. since November 2023 and holds the position of Contract CFO at Tandem Innovation Group Inc. since February 2020. Previously, David Hyman has held multiple CFO roles, including at Rakovina Therapeutics Inc. and Mesentech, as well as serving as CFO for TheraCann International and Merrco Payments Inc. Additionally, David Hyman was Vice President at Camcor Partners and worked as an Equity Analyst at Raymond James Financial, Inc. David Hyman began professional career at Deloitte Canada as a Senior Manager in Financial Advisory Services. David Hyman earned a Bachelor of Commerce (B.Com.) degree in Accounting from the University of Calgary between 1990 and 1995.
This person is not in any teams
This person is not in any offices
Medicenna Therapeutics
1 followers
Medicenna Therapeutics is a clinical-stage immunotherapy company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines (ECs). Their mission is to become the leader in the development and commercialization of targeted ECs and Superkines for the treatment of a broad range of cancers and immune-mediated diseases.